Patterns of photoprotection following CDKN2A/p16 genetic test reporting and counseling

Department of Psychology, University of Utah, Salt Lake City, Utah, USA.
Journal of the American Academy of Dermatology (Impact Factor: 4.45). 03/2009; 60(5):745-57. DOI: 10.1016/j.jaad.2008.12.034
Source: PubMed


The impact of melanoma genetic testing and counseling on photoprotective behaviors is unknown.
To determine if genetic testing and counseling alter compliance with photoprotection recommendations.
Reported use of sunscreen, protective clothing, and sun avoidance by 59 members of CDKN2A/p16-mutation positive pedigrees was assessed as a function of mutation status and melanoma history, before, immediately after, and 1 month following test reporting.
Intentions to practice all photoprotective behaviors increased in all participant groups (P < .0001). At 1 month, 33% of participants reported the adoption of a new photoprotective behavior. Subpopulation analyses identified different patterns of change in photoprotection relative to baseline (P < .005), with no net decline in any group.
This initial study of CDKN2A/p16 families is small and awaits replication in a larger sample.
Melanoma genetic testing and counseling enhanced intentions to implement photoprotective strategies and did not result in reduced compliance in the CDKN2A/p16-subpopulation.

13 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Little is known about how religious beliefs are related to the understanding and management of genetic test results in cancer-prone families. Twenty-five adult US members of The Church of Jesus Christ of Latter-day Saints (LDS) who had received CDKN2A/p16 genetic test results for familial melanoma were asked 1 year later to describe any religious or spiritual beliefs that were important to their understanding of their genetic test results and to complete concurrent assessments of perceived control, cancer fatalism, and adherence to sun-protection recommendations. Overall, 88% of participants listed one or more religious themes as important to their understanding and/or management of genetic test results, with no differences between carriers and non-carriers. All religious themes were significant predictors of at least one sun-protection or UV risk behavior in the past 6 months. Personal agency/responsibility for health (listed by 60%) predicted greater perceived control over melanoma development among participants with a history of melanoma and decreased reports of being tanned in the past 6 months. Belief that cancer was God's will (56%) predicted greater beliefs about the lethality of melanoma, but was unrelated to perceived control or other fatalistic beliefs. Forty percent of respondents reported emotional benefits of religious faith in managing their own or a family member's cancer risk. Twenty-four percent indicated that scientific and medical advances were gifts from God. Participants who indicated that their religious beliefs were unrelated to their understanding of genetic test results (16%) reported fewer sun-protection behaviors and much more frequent sunburns and tans. These results suggest that even in a sample with strong endorsement of cancer as God's will, religious beliefs are associated with greater perceived control over melanoma development and greater adherence to prevention recommendations in high-risk patients. Implications for understanding the relation between religious beliefs and the management of elevated cancer risk are discussed.
    Archive for the Psychology of Religion / Archiv für Religionspychologie 12/2009; 32(1):87-112. DOI:10.1163/008467210X12626615185784 · 0.34 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Genetic testing of minors is controversial, as ethical considerations depend on multiple aspects of the particular disease and familial context. For melanoma, there is a well-established and avoidable environmental influence and a documented benefit of early detection. We surveyed 61 CDKN2A/p16 mutation-tested adults from two kindreds about their attitudes toward genetic testing of minors immediately posttesting and 2 years later. Overall, 86.9% expressed support of melanoma genetic testing of minors, with the importance of risk awareness (77.4%) and the likelihood of improved prevention and screening behaviors (69.8%) as the most frequently cited potential benefits. Among mutation carriers, 82.6% wanted genetic testing for their own children. These preferences remained stable over a 2-year period. Most respondents (62.3%) favored complete involvement of their children in genetic counseling and test reporting; 19.7% suggested that children be tested but not informed of the results. Concerns about inducing psychological distress or compromising children's decision autonomy were infrequently cited. Testing preferences did not vary by respondent age, gender, or melanoma history. Respondents strongly supported melanoma genetic testing of minors, with most citing improved health behavior as a likely outcome. We discuss options for melanoma genetic counseling and testing of minors.
    Genetics in medicine: official journal of the American College of Medical Genetics 11/2010; 12(12):823-38. DOI:10.1097/GIM.0b013e3181f87278 · 7.33 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: CDKN2A/p16 mutations confer 76% lifetime risk of melanoma and up to 17% lifetime risk of pancreatic cancer. Our objective was to determine the short- and long-term impact of CDKN2A/p16 genetic counseling and test reporting on psychological distress, cancer worry, and perceived costs and benefits of testing. Prospective changes in anxiety, depression, and cancer worry following CDKN2A/p16 counseling and test reporting were evaluated at multiple assessments over 2 years among 60 adult members of melanoma-prone families; 37 participants completed the 2-year follow-up. Quantitative and qualitative assessments of the costs and benefits of testing were carried out. Outcomes were evaluated among unaffected noncarriers (n = 27), unaffected carriers (n = 15), and affected carriers (n = 18). Reported anxiety and depression were low. For carriers and noncarriers, anxiety decreased significantly throughout the 2-year period, whereas depression and melanoma worry showed short-term decreases. Worry about pancreatic cancer was low and decreased significantly. In all groups, test-related distress and uncertainty were low, regret was absent, and positive experiences were high. All participants (>93% at each assessment) reported at least one perceived benefit of genetic testing; only 15.9% listed any negative aspect. Carriers reported increased knowledge about melanoma risk and prevention (78.3%) and increased prevention and screening behaviors for self and family (65.2%). Noncarriers reported increased knowledge (95.2%) and emotional benefits (71.4%). Among US participants familiar with their hereditary melanoma risk through prior epidemiological research participation, CDKN2A/p16 genetic testing provides multiple perceived benefits to both carriers and noncarriers without inducing distress in general or worry about melanoma or pancreatic cancer. Copyright © 2011 John Wiley & Sons, Ltd.
    Psycho-Oncology 10/2011; 22(2):276-89. DOI:10.1002/pon.2080 · 2.44 Impact Factor
Show more